Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1801-1820 of 3,900 trials

Follicular Lymphoma: Tazemetostat with Lenalidomide and Rituximab

We are studying the safety and effectiveness of tazemetostat combined with lenalidomide and rituximab in adults with relapsed or refractory follicular lymphoma. This trial compares the new treatment to a placebo to see how well it works.

Relapsed/Refractory Follicular Lymphoma>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesHematologyOncology

DAY101 for Pediatric Brain Cancer and Solid Tumors

We are studying the effects of DAY101 in children aged 6 months to 25 years with low-grade glioma or advanced solid tumors. The goal is to see if it helps shrink tumors and to assess its safety.

Malignant Glioma>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Mpox Booster Vaccine: Fractional vs. Full Dose

We are studying whether a smaller booster dose of the MVA-BN vaccine is as effective as the standard dose in adults. This trial will also look at the safety and immune response of both doses.

Mpox (Monkeypox)3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

External Cephalic Version: Propofol vs. Spinal Analgesia

We are comparing the use of Propofol and spinal analgesia for sedation during a procedure to turn breech babies. Our goal is to find out which method has a higher success rate and fewer complications.

External Cephalic Version>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsInternal Medicine

Soft Tissue Sarcomas: HDM201 and Pazopanib Study

We are evaluating a new treatment combining HDM201 and Pazopanib for patients with advanced soft tissue sarcomas. The goal is to understand its clinical impact on those with P53 wild-type tumors.

Soft Tissue Sarcoma>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Prostate Cancer: Personalized Radiotherapy and Hormone Therapy

We are studying whether using AI to customize radiotherapy and hormone treatment can help prostate cancer patients while reducing the overall treatment time. This trial is for those with high-risk localized prostate cancer.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Soft Tissue Sarcoma: MEK and PDL1 Inhibitor Combination

We are studying a new treatment combining two medications for patients with advanced soft tissue sarcoma. This trial aims to confirm safety and evaluate how well the treatment works in both children and adults.

Advanced or Metastatic CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Soft Tissue Sarcomas: Atezolizumab with Radiotherapy

We are studying whether adding an immunotherapy drug to radiotherapy helps patients with localized soft tissue sarcomas achieve better treatment outcomes. The trial will also look at the safety and immune response to this combination.

Localized Soft Tissue Sarcoma3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

VEXAS Syndrome: Azacitidine Treatment Study

We are studying whether Azacitidine can help reduce symptoms and improve health in patients with VEXAS Syndrome. The trial will also assess the safety of this treatment and its impact on patients' quality of life.

VEXAS Syndrome>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyRheumatology

Membranous Nephropathy: Personalized Rituximab Treatment Study

We are exploring whether an AI-driven personalized treatment plan for membranous nephropathy is more effective than standard rituximab treatment. This study aims to improve patient outcomes and remission rates.

Acute GlomerulonephritisMembranous Nephropathy6-12 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesNephrology

Breast Cancer: Fezolinetant for Hot Flashes

We are studying whether fezolinetant can help reduce hot flashes in women with hormone receptor-positive breast cancer receiving hormone therapy. The trial also looks at how this treatment affects quality of life and sleep.

Hot Flashes1-2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteEndocrinologyOncology

Dementia with Lewy Bodies: Ambroxol Study

We are investigating whether Ambroxol can improve cognitive and functional abilities in people with early Dementia with Lewy Bodies. The study also looks at its effects on sleep disturbances and other related symptoms.

Dementia with Lewy Bodies1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessStandard MedicinesNeurologyPsychiatry

GEN1047 for Solid Tumors - First in Human Trial

We are testing a new treatment called GEN1047 for people with malignant solid tumors. The study aims to find the safest dose and evaluate how well it works against cancer.

Malignant Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Hidradenitis Suppurativa: Lutikizumab Study

We are evaluating the effectiveness and safety of lutikizumab for treating moderate to severe hidradenitis suppurativa in adults and adolescents. This study compares lutikizumab to a placebo to see how well it works.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatology

Axial Spondyloarthritis and Psoriatic Arthritis: Ixekizumab Study

We are examining how ixekizumab affects inflammation in patients with axial spondyloarthritis and psoriatic arthritis. This study uses whole-body MRI to measure changes in joints and entheses.

Psoriatic ArthritisAxial Spondyloarthritis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOrthopedics and TraumatologyRheumatology

Stroke Treatment: Anesthesia vs. Sedation

We are comparing general anesthesia to sedation with high-flow nasal cannula for patients undergoing treatment for acute ischemic stroke. Our goal is to see which method leads to better recovery and fewer complications.

Acute Ischemic Stroke>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOtolaryngology

Knee Osteoarthritis: Diclofenac vs. Placebo

We are studying how diclofenac affects knee pain compared to a placebo in people with knee osteoarthritis. The trial also looks at how a special script may change patients' pain experiences.

Knee Osteoarthritis≤3 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Safety Study of IMP761 Immunosuppressive Antibody

We are testing the safety of a new immunosuppressive antibody in healthy volunteers. This study aims to understand how the antibody affects the body before further testing in patients.

Autoimmunity1-2 yearsSafety phase (I)Infectious Diseases

Whipple's Procedure: Antibiotic Treatment Comparison

We are studying whether pre-emptive antibiotics can lower the risk of infections after Whipple's surgery compared to standard antibiotic treatment. This trial aims to improve recovery outcomes for patients undergoing this procedure.

Pancreatoduodenectomy with High Risk for Contaminated Bile>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInfectious Diseases

Colorectal Cancer: SGM-101 Imaging Study

We are testing a new imaging agent to help surgeons detect brain metastases from colorectal cancer during surgery. This study aims to see how well it works and its safety for patients.

Brain Metastases1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesNeurologyOncology